cognitive cybersecurity intelligence

News and Analysis

Cyber-Security Provider BIO-key Reports Q3 and Year-to-Date

WALL, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) and large-scale identity solutions, featuring Identity-Bound Biometrics (IBB), today reported results for its third…

Source: news.google.com – Read more

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight

Y chromosome loss creates hidden cancer vulnerability in men

A study initiated by a University of Arizona Cancer Center physician-scientist Dr. Dan Theodorescu revealed that the loss of the Y chromosome in men’s body

The True Cost of Focusing on Cost Instead of Cost-Effectiveness

When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is

News and Analysis

Cyber-Security Provider BIO-key Reports Q3 and Year-to-Date

Subscribe to newsletter

More Posts

Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

Y chromosome loss creates hidden cancer vulnerability in men

The True Cost of Focusing on Cost Instead of Cost-Effectiveness

Products

Solutions

Healthcare cybersecurity

Healthcare Threat Intelligence

Use Cases

News and Analysis

Insights

Company